MedTrace Logo

Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

NCT06771960 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-02-21

No results posted yet for this study

Summary

EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.

Conditions

  • Lung Cancer (NSCLC)

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Guibin Qiao · Guangdong Provincial People's Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-12-01
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06771960 on ClinicalTrials.gov